Crestor

Crestor (rosuvastatin calcium) is a popular statin used along with diet and exercise to lower bad cholesterol by blocking liver enzymes. Doctors also prescribe the drug to slow plaque buildup in arteries and to prevent heart disease, heart attacks, strokes and other cardiovascular diseases.

Crestor 10mg Pills
Crestor Facts
  1. Uses Lower bad cholesterol known as LDL; increase good cholesterol, or HDL; lower the level of triglycerides, which is fat in blood; slow plaque buildup in arteries; reduce the risk of heart attacks and strokes in men over 50 years old and women over 60 years old who have certain risk factors other than known heart disease
  2. Approved to Treat Men and women who cannot control their cholesterol with just diet and exercise; children between the ages of 8 and 17 who have heterozygous familial hypercholesterolemia; children between the ages of 7 and 17 who have homozygous familial hypercholesterolemia
  3. Common Side Effects Weakness, muscle aches, headache, nausea and abdominal pain
  4. Manufacturer AstraZeneca

Crestor is part of a family of cholesterol-lowering drugs known as statins that includes Lipitor, Zocor and Lescol. The medication is designed to work with proper diet and exercise to lower bad cholesterol and slow the buildup of fatty deposits in the walls or blood vessels, which may prevent heart attacks and strokes.

Rosuvastatin works in two ways:
  1. It reduces the amount of cholesterol the liver produces by blocking a key enzyme.
  2. It allows the liver to take in and break down cholesterol already in the blood.

The active ingredient is rosuvastatin calcium. Rosuvastatin has been shown to reduce the risk of heart attack over 1.9 years of use. But there have been no long-term studies examining the effects of taking it or any other statins for as long as 20 or 30 years, which is the length of time many people will take the medicine.

Generic Statin Pack
Crestor is part of a class of drugs called statins.

The U.S. Food and Drug Administration first approved the medication in 2003 for use in adults with high levels of “bad cholesterol” and a history of heart disease. In 2010, the FDA approved the drug for additional uses including prevention of heart attacks, strokes and death among fairly healthy people with elevated C-reactive protein (CRP) levels, which is a maker of inflammation.

AstraZeneca manufactures the drug, which is approved for use in more than 115 countries. Generic versions have been available since 2016.

Dosages and Precautions

Crestor comes in tablets that vary in color, shape and size depending on the dosage. Doses range from 5 mg to 40 mg taken once a day at any time, with or without food.

The usual starting dose is 10 mg to 20 mg once daily. But there are notable exceptions.

Crestor tablets dosage

In March 2004, the FDA required updates to the drug’s package insert to include new dosage instructions for patients with Asian ancestry. The change told doctors to consider starting Asian patients at just 5 mg once daily.

The drug’s label cites studies that have shown rosuvastatin levels twice as great in Asian subjects compared to Caucasian patients who took the same dose. Such elevated levels can increase the risk of muscle damage.

The label warns that people with a known hypersensitivity to ingredients in the drug should not take it. Rosuvastatin is also not recommended for people with active liver disease, women who are pregnant or who may become pregnant, or nursing mothers.

Side Effects and Warnings

The most common side effects of Crestor may include muscle aches, weakness, abdominal pain, nausea and headache. The drug has also been associated with a risk of cataracts, kidney and liver damage, and a possible increased risk of developing diabetes.

Let your doctor know if you experience unexplained muscle pain or weakness, or if you continue to have muscle problems even after your doctor has told you to stop taking Crestor. You should also alert your doctor if your urine is dark, your skin or eyes are yellowing, your stomach hurts or your appetite has changed. These could be signs of rare but serious skeletal muscle effects such as myopathy or rhabdomyolysis.

The FDA has required AstraZeneca to add warnings to Crestor’s label based on clinical trials and postmarket surveillance.

Required warnings include:
LIVER ENZYME ABNORMALITITES
Recommends doctors test liver enzymes before prescribing the medication and during treatment if the patient has symptoms of liver problems
COGNITIVE ISSUES
Includes side effects such as memory loss or impairment, confusion, forgetfulness and amnesia
LOVASTATIN DRUG INTERACTIONS
Warns rosuvastatin should never be taken with Mevacor (lovastatin), another cholesterol medicine
BLOOD SUGAR INCREASES
Advises increases in blood sugar levels have been reported with use of statins
PROTEASE INHIBITOR DRUG INTERACTIONS
Cautions taking the drug with HIV or hepatitis C virus medicines called protease inhibitors may raise statin levels in the blood (This increases the risk for muscle injury, including rhabdomyolysis, which can result in kidney failure)

Recall Petition

Public Citizen petitioned the FDA in 2004 and 2005 to recall Crestor. The advocacy organization’s health research group documented cases of patients who developed rhabdomyolysis after taking the drug.

Rhabdomyolysis is a severe form of muscle damage that can lead to permanent kidney damage, coma and sometimes death.

Public Citizen demanded the FDA recall the drug to prevent further incidents of rhabdomyolysis, kidney failure or kidney damage. The FDA denied the petitions, but the agency later required AstraZeneca to add warnings to the drug’s label about a risk of developing rhabdomyolysis with acute renal failure.

Renal Kidney Warning
Expand
Source: Crestor Label

In its 2017 annual report, AstraZeneca acknowledged it had faced several Crestor lawsuits over rhabdomyolysis and other injuries.

“In the US, AstraZeneca was defending a number of lawsuits alleging multiple types of injuries caused by the use of Crestor, including diabetes mellitus, various cardiac injuries, rhabdomyolysis, and/or liver and kidney injuries,” the report stated. “AstraZeneca has resolved all active claims with regard to this matter.”

International Safety Concerns

While most statins are very similar, Crestor is one of the two most powerful statins at reducing LDL, or “bad” cholesterol, levels. The other is Lipitor.

This increased potency has caused some regulatory bodies outside of the United States to approach Crestor’s approval with caution. Higher doses and stronger statins pose a greater risk of rare but serious side effects, including a potentially life-threatening muscle disease called myopathy.

In June 2004, AstraZeneca released a revised package insert for use in the European Union.

“The changes to the European labeling are in response to postmarketing spontaneous adverse event reports in patients receiving Crestor and highlight certain patient populations who may be at an increased risk for serious muscle toxicity (myopathy) associated with Crestor use, especially at the highest approved dose of 40 mg,” the FDA said in a public health advisory.

Lingering safety concerns prompted Germany, Norway, Poland, Malta and Spain to hold off on approval. While most EU countries approved the drug in 2003 or shortly after, the five holdouts did not grant approval until 2008, according to Reuters.

Germany is the largest national economy in Europe. Winning approval to market the medication there helped the drug’s global sales grow by more than $900 million in following year, according to the company’s 2010 annual report.

Generic Versions

AstraZeneca’s patent on Crestor expired in the United States on July 8, 2016. This allowed other companies to seek FDA approval for generic versions and begin manufacturing the approved ones.

As of January 2019, at least 20 manufacturers had received FDA approval to manufacture generic versions of rosuvastatin calcium. The agency says the generic drugs it approves have the same quality and strength as brand-name versions.

Crestor sales dropped 70 percent from $1.2 billion in 2016 to $373 million in 2017. However, AstraZeneca noted in its 2017 annual report that the drug had remained one of its top sellers.

In the face of growing generic competition, the drug still generated more than $2.36 billion for the company worldwide. But that represented a 30 percent global decline from the previous year.

AstraZeneca said in the report it expected to lose $1 billion in sales revenues in 2018 “in particular through the loss of exclusivity for Crestor in Europe and Japan.”

In third quarter filings for 2018, the company reported year-to-date United States sales had dropped by 48 percent, and European sales had dipped by 69 percent.

Please seek the advice of a medical professional before making health care decisions.

Related Pages
Terry Turner
Written By Terry Turner Writer

Terry Turner has been writing articles and producing news broadcasts for more than 25 years. He covers FDA policy, proton pump inhibitors, and medical devices such as hernia mesh, IVC filters, and hip and knee implants. An Emmy-winning journalist, he has reported on health and medical policy issues before Congress, the FDA and other federal agencies. Some of his qualifications include:

  • American Medical Writers Association (AMWA) and The Alliance of Professional Health Advocates member
  • Centers for Disease Control and Prevention Health Literacy certificates
  • Original works published or cited in Washington Examiner, MedPage Today and The New York Times
  • Appeared as an expert panelist on hernia mesh lawsuits on the BBC
Edited By

32 Cited Research Articles

  1. Associated Press. (2011, December 19). Lipitor Sales Plunge after World’s Top-Selling Drug Gets U.S. Generic Competition. Retrieved from http://www.nydailynews.com/life-style/health/lipitor-sales-plunge-world-top-selling-drug-u-s-generic-competition-article-1.994136
  2. AstraZeneca. (2010). 2010 Annual Report. Retrieved from https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2010-Annual-Report-English.pdf
  3. AstraZeneca. (2015). 2015 Annual Report. Retrieved from https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/AZ_Annual_Report_2015.pdf
  4. AstraZeneca. (2016, May). Crestor. Retrieved from https://www.crestor.com/cholesterol-medicine/faqs.html
  5. AstraZeneca. (2017). 2017 Annual Report. Retrieved from  https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2017/annualreport2017.pdf
  6. AstraZeneca. (2018, January). Crestor. Retrieved from  https://www.crestor.com/cholesterol-medicine/faqs.html
  7. AstraZeneca. (2018, November 8). Year-to-Date and Q3 2018 Results. Retrieved from https://www.astrazeneca.com/content/dam/az/PDF/2018/Q3/Year-To-Date_and_Q3_2018_Results_announcement.pdf
  8. AstraZeneca. (n.d.). Annual Reports; Archive. Retrieved from  https://www.astrazeneca.com/investor-relations/annual-reports.html
  9. Cha, A.E. (2016, November 13). New Statin Guidelines: Everyone 40 and Older Should Be Considered for The Drug Therapy. Retrieved from  https://www.washingtonpost.com/news/to-your-health/wp/2016/11/13/new-statin-guidelines-everyone-age-40-should-be-considered-for-the-drug-therapy/?utm_term=.461c1e4d371b
  10. Chogtu, B., Magazine, R. and Bairy, K.L. (2015, March 15). Statin Use and Risk of Diabetes Mellitus. World Journal of Diabetes. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360430/
  11. Consumer Reports. (2014, March). Evaluating Statin Drugs to Treat: High Cholesterol and Heart Disease. Retrieved from  https://www.consumerreports.org/health/resources/pdf/best-buy-drugs/StatinsUpdate-FINAL.pdf
  12. Crestor. (n.d.). How Crestor Works. Retrieved from  https://www.crestor.com/how-to-lower-cholesterol/how-does-rosuvastatin-calcium-work.html
  13. Hla, D. et al. (2018, April 9). Assessing Severity of Statin Side Effects: Fact versus Fiction. American College of Cardiology. Retrieved from https://www.acc.org/latest-in-cardiology/articles/2018/04/09/13/25/assessing-severity-of-statin-side-effects
  14. Liao, J.K. (2007, February 1). Safety and Efficacy of Statins in Asians. Retrieved from  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651637/
  15. NIH. (2016, September). Drug and Device News; Generic Approvals. Retrieved from  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010262/
  16. NIH. (2018, February 7). C-reactive protein. Retrieved from  https://medlineplus.gov/ency/article/003356.htm
  17. O’Riordan, M. (2012, August 13). JUPITER Analysis Helps Assuage Fears About Diabetes Risk with Statins. Retrieved from  http://www.medscape.com/viewarticle/769024?pa=mcx5JvCyQx3QyO2lA13c1jl%2BPAkWNZ1veTw4em5pa8cZhza5pEO20kHYJlh37jtAJyGvMX%2Fu%2BWdIXoARf%2FT0zw%3D%3D
  18. Pollack, A. (2016, July 20). Generic Crestor Wins Approval, Dealing Blow to AstraZeneca. Retrieved from  https://www.nytimes.com/2016/07/21/business/generic-crestor-wins-approval-dealing-a-blow-to-astrazeneca.html
  19. Reuters. (2008, October 30). Astra Drug Crestor Finally Gets German Green Light. Retrieved from http://www.reuters.com/article/astrazeneca-crestor-idUSLU21831520081030
  20. Ridker, P.M. et al. (2008, November 20). Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. Retrieved from   http://www.nejm.org/doi/full/10.1056/NEJMoa0807646#t=article
  21. Ross. G. (2015, December 4). Too Few Americans Take Statins, CDC Study Reveals. Retrieved from  http://www.acsh.org/news/2015/12/04/cdc-study-reveals-that-too-few-americans-are-on-statins
  22. Sattar, N. et al. (2010, February 16). Statins and Risk of Incident Diabetes: A Collaborative Meta-Analysis of Randomised Statin Trials. The Lancet. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20167359/
  23. U.S. Food and Drug Administration. (2004, June 9). Public Health Advisory for Crestor (rosuvastatin). Retrieved from https://wayback.archive-it.org/7993/20170722190843/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051719.htm
  24. U.S. Food and Drug Administration. (2015, July 10). Rosuvastatin Calcium (Marketed as Crestor) Information. Retrieved from  https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109095.htm
  25. U.S. Food and Drug Administration. (2016, June 8). FDA Approves First Generic Crestor. Retrieved from  https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm498373.htm
  26. U.S. Food and Drug Administration. (2018, January 4). Controlling Cholesterol with Statins. Retrieved from  https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm
  27. U.S. Food and Drug Administration. (2018, November 9). Crestor Label. Retrieved from  https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf
  28. U.S. Food and Drug Administration. (2019, January 4). Drugs@FDA: FDA Approved Drug Products. Rosuvastatin. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/
  29. U.S. Preventative Services Task Force. (2016, November). Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication. Retrieved from  https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/statin-use-in-adults-preventive-medication1
  30. U.S. Preventative Services Task Force. (2017, May). About the USPSTF. Retrieved from  https://www.uspreventiveservicestaskforce.org/Page/Name/about-the-uspstf
  31. Victoria State Government. (n.d.). Cholesterol. Retrieved from https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/cholesterol
  32. Wolfe, S.M. (2004, June 26). Dangers of Rosuvastatin Identified before and after FDA Approval. Retrieved from  http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2804%2916513-6/fulltext
View All Sources
Who Am I Calling?

Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.

Drugwatch's sponsors support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our sponsors page.

(888) 645-1617